Sinopharm Hyundai announced that recently, its wholly-owned subsidiary Sinopharm received the “Drug Registration Certificate” for ketamine hydrochloride injections approved and issued by the State Drug Administration. The specification is 2 ml: 0.1 g, and the registration classification is 3 types of chemicals. Sinopharm is the first company to be deemed to have passed the consistency evaluation. Up to now, the project has invested about 6.831,100 yuan in R&D. This will enrich the company's product range in the anesthesiology and analgesia sector and enhance competitiveness, but there is no significant impact on current business performance, and there is uncertainty about drug sales.

Sinopharm Hyundai announced that recently, its wholly-owned subsidiary Sinopharm received the “Drug Registration Certificate” for ketamine hydrochloride injections approved and issued by the State Drug Administration. The specification is 2 ml: 0.1 g, and the registration classification is 3 types of chemicals. Sinopharm is the first company to be deemed to have passed the consistency evaluation. Up to now, the project has invested about 6.831,100 yuan in R&D. This will enrich the company's product range in the anesthesiology and analgesia sector and enhance competitiveness, but there is no significant impact on current business performance, and there is uncertainty about drug sales.